J&J Can't Ax Pfizer Antitrust Suit Over Remicade Biosimilar
Law360 (August 10, 2018, 8:29 PM EDT) -- Pfizer Inc. has credibly shown that Johnson & Johnson may have flouted antitrust laws by coercing health insurers into not covering biosimilar versions of biologic Remicade, a Pennsylvania federal judge said in a ruling released Friday.
The ruling from U.S. District Judge J. Curtis Joyner rejected J&J’s bid to sink litigation that Pfizer launched in 2017. Judge Joyner found that Pfizer’s suit plausibly alleges that J&J breached the Sherman Act and the Clayton Act by threatening to deny rebates for Remicade if health insurers covered rival biosimilar products, such as Pfizer’s Inflectra.
According to Judge Joyner, Pfizer has supplied “detailed allegations regarding...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!
Kirkland & Ellis LLP has redefined what it means to be the biggest of BigLaw — weighing in at 2,116 attorneys by year end 2018 and becoming the first firm since Law360 began tracking law firm head counts to top 2,000 U.S.-based attorneys.